CTNI-67. EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN EXPANDED DATASET

BACKGROUND: TRK fusion proteins are oncogenic drivers of various CNS and non-CNS tumors. Larotrectinib, a highly selective FDA- and EMA-approved TRK inhibitor, demonstrated an objective response rate (ORR) of 79% across various non-CNS cancers (Hong et al. Lancet Oncol. 2020). We report data in an e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Perreault, Sébastien, Doz, François, Drilon, Alexander, Geoerger, Birgit, Boni, Valentina, Chisholm, Julia, Dubois, Steven G, Grilley-Olson, Juneko E, Hong, David S, Italiano, Antoine, Kang, HyoungJin, Nysom, Karsten, Øra, Ingrid, Owens, Cormac, Schulte, Johannes H, Tahara, Makoto, Ziegler, David, Ellezam, Benjamin, Reeves, John A, Fellous, Marc, De La Cuesta, Esther, Laetsch, Theodore W, van Tilburg, Cornelis M
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651037/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.233
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados